Business Context and Reporting Period
The provided filing is Neuralstem, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015, not a filing for Palisade Bio, Inc. Neuralstem develops regenerative medicine therapies based on human neural stem cells and small-molecule compounds. Its programs were in preclinical or clinical development, with no products approved for commercial sale.
As of June 30, 2015, the company had 25 full-time employees and three full-time independent contractors. Its lead programs included NSI-189 for major depressive disorder and NSI-566 for ALS, chronic spinal cord injury, and stroke-related motor deficits.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | 2015: $2,500; 2014: $5,000 | 2015: $5,417; 2014: $9,167 |
| Research and development expense | 2015: $3.31 million; 2014: $2.00 million | 2015: $6.50 million; 2014: $3.63 million |
| General and administrative expense | 2015: $1.68 million; 2014: $1.52 million | 2015: $3.12 million; 2014: $5.07 million |
| Operating loss | 2015: $4.99 million; 2014: $3.51 million | 2015: $9.61 million; 2014: $8.69 million |
| Net loss | 2015: $5.45 million; 2014: $6.75 million | 2015: $10.50 million; 2014: $12.67 million |
| Loss per share | 2015: $0.06; 2014: $0.08 | 2015: $0.12; 2014: $0.15 |
| Operating cash flow | Not separately presented | 2015: $(9.52) million; 2014: $(5.12) million |
- Revenue consisted solely of licensing fees; the company generated no product sales.
- Total cash and short-term investments were $23.68 million at June 30, 2015, compared with $27.53 million at December 31, 2014. Cash and cash equivalents were $8.65 million.
- Total assets were $26.37 million and stockholders’ equity was $14.54 million at June 30, 2015.
- Long-term secured debt was approximately $9.5 million, including current and non-current portions. The debt bears interest at a variable rate with a 10% floor and is secured by substantially all assets, including intellectual property.
- The company had an accumulated deficit of $161.56 million and has incurred operating losses and negative operating cash flow since inception.
- Six-month financing cash inflows were $5.85 million, including $2.93 million from an at-the-market stock offering and $3.07 million from warrant exercises.
Material Changes Versus the Prior Comparable Period
- Six-month research and development expense increased 79%, or $2.87 million, primarily from higher project and laboratory costs, payroll, headcount, and stock-based compensation.
- Six-month general and administrative expense decreased 38%, or $1.95 million, primarily because 2014 included approximately $2.0 million of non-cash stock-based compensation tied to a performance-based warrant milestone and higher legal expense.
- Six-month operating cash use increased 86%, from $5.12 million to $9.52 million, reflecting greater operating spending and the higher development activity.
- Net loss improved year over year because 2014 included a $3.11 million warrant modification expense and a $334,000 derivative fair-value loss; these items did not recur in 2015.
- Shares outstanding increased to 90.36 million at June 30, 2015 from 87.79 million at December 31, 2014. Approximately 42.6 million shares were reserved for outstanding options, warrants, and other awards, creating substantial potential dilution.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected research and development expense to increase as clinical programs progressed, subject to available funding. The company did not expect to be profitable in the next several years.
- Management planned to advance NSI-189 toward a Phase II major depressive disorder trial expected to begin in 2015, and to prepare additional NSI-566 trials for ALS and stroke. The chronic spinal cord injury Phase I trial treated its last patient in July 2015, after the reporting date.
- Management stated that substantial additional capital would be required to fund research, clinical trials, regulatory approvals, manufacturing, facilities, and working capital. Future financing could involve equity, debt, licensing arrangements, or grants and may not be available on acceptable terms.
- Debt payments were scheduled to change from interest-only payments through September 2015 to approximately $461,000 of monthly principal and interest payments from October 2015 through March 2017, followed by an approximately $2.1 million balloon payment in April 2017.
- Clinical, regulatory, manufacturing, reimbursement, intellectual-property, competition, and third-party outsourcing risks could delay or prevent commercialization. No product candidate had received regulatory approval.
- The company was transitioning some clinical-grade spinal cord stem-cell manufacturing in-house while continuing to rely substantially on third-party manufacturers and clinical research organizations.
- Management concluded that disclosure controls and procedures were not effective as of June 30, 2015 because of inadequate operation of existing controls. Remediation included hiring a full-time CFO, enhanced whistleblower protocols, improved expense-disbursement documentation, and increased Audit Committee oversight. Management did not anticipate a restatement.
- On July 22, 2015, a court dismissed with prejudice the StemCells, Inc. patent litigation after determining that StemCells lacked standing. Management stated that other routine litigation was not expected to have a material adverse effect.
- In July 2015, after the reporting period, the company’s stock began trading on the NASDAQ Capital Market.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing names Neuralstem, Inc., while the request metadata names Palisade Bio, Inc.
- Verify cash runway against the company’s $9.52 million six-month operating cash burn, planned clinical expansion, and scheduled debt amortization beginning October 2015.
- Review the terms, covenants, collateral, and repayment schedule of the approximately $10 million amended secured credit facility.
- Assess potential dilution from approximately 42.6 million reserved shares, including outstanding options and warrants, relative to approximately 90.4 million shares outstanding.
- Evaluate the status and results of the planned NSI-189 and NSI-566 clinical trials, including whether stated 2015 milestones were achieved.
- Monitor remediation of the ineffective disclosure controls and determine whether later filings report effective controls or additional deficiencies.
- Confirm the final legal status and any continuing intellectual-property consequences of the dismissed StemCells litigation.